Evidence map›Paper›PMID 41071735›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Vaccine Treatment and Evaluation Units: Why Support a "Ready Base" of Clinical Trial Sites?

Emily J Erbelding, Jeanne M Marrazzo

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emily J ErbeldingDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Jeanne M MarrazzoNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Funding

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
NIAID NIH HHS UM1 AI148684
6 · The paper itself

Abstract

The National Institute of Allergy and Infectious Diseases has funded a clinical trial infrastructure to advance products and strategies to improve treatment and prevention of infectious diseases. This infrastructure includes dedicated research clinics, such as the Vaccine and Treatment Evaluation Units (VTEUs). For more than 6 decades, the VTEUs have maintained quality systems to advance investigational products to licensure by conducting trials that de-risk private sector investment in clinical development. They have developed novel clinical trial approaches, such as controlled human challenge models, responded rapidly to pandemic threats, engaged impacted communities across a variety of diseases, and provided mentorship and training to the next generation of clinical investigators.

Indexed as

Clinical Trials as TopicVaccine DevelopmentVaccinesHumansNational Institute of Allergy and Infectious Diseases (U.S.)United StatesVaccinesclinical trialsinfrastructurepandemic responseresearch infrastructure

Identifiers

PMID41071735
PMCPMC12640205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.